K-Ras-IN-1 is a potent and selective inhibitor of the K-Ras protein, particularly targeting the G12C mutation, which is commonly found in various cancers. It works by covalently binding to the mutated cysteine residue, locking K-Ras in an inactive state, thereby suppressing downstream signaling pathways such as MAPK that drive cell proliferation and survival. This compound is primarily used in cancer research, especially in studies focused on non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic ductal adenocarcinoma, where K-Ras mutations are prevalent. It serves as a valuable tool for validating K-Ras as a therapeutic target and for studying resistance mechanisms to Ras inhibition. In preclinical studies, K-Ras-IN-1 has shown antitumor activity by reducing tumor growth in xenograft models. It is also used in combination studies with other targeted agents, such as inhibitors of MEK, EGFR, or SHP2, to overcome adaptive resistance and enhance therapeutic efficacy. Due to its specificity and mechanism of action, K-Ras-IN-1 supports the development of next-generation Ras inhibitors and contributes to the understanding of oncogenic signaling networks in solid tumors.